Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison

Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison

Abstract Introduction Dupilumab and lebrikizumab have demonstrated efficacy in atopic dermatitis (AD) clinical trials; however, no direct comparisons exist. Methods Efficacy outcome achievement (dupilumab and lebrikizumab with topical corticosteroids [TCS]) at 16 weeks and efficacy outcomes maintena...

Full description

Saved in:
Bibliographic Details
Main Authors: Sonja Ständer, Andreas Pinter, Firas G. Hougeir, Patricia Guyot, Yingxin Xu, Amy H. Praestgaard, Nick Freemantle, Ana B. Rossi, Gaëlle Bégo-Le-Bagousse, Zhixiao Wang, Kerry Noonan, Mike Bastian
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-07-01
Series:Dermatology and Therapy
Subjects:
Atopic dermatitis
Bucher indirect treatment comparison
Dupilumab
Indirect treatment comparison
Lebrikizumab
Online Access:https://doi.org/10.1007/s13555-025-01479-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s13555-025-01479-y

Similar Items